Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
出版年份 2023 全文链接
标题
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 24, Issue 5, Pages 535-552
出版商
Elsevier BV
发表日期
2023-05-03
DOI
10.1016/s1470-2045(23)00144-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors
- (2022) David John Allsup et al. AMERICAN JOURNAL OF HEMATOLOGY
- Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
- (2022) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial
- (2022) Tait D. Shanafelt et al. BLOOD
- A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia
- (2021) Dena R. Howard et al. Trials
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
- (2019) Ilaria Del Giudice et al. Frontiers in Oncology
- Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
- (2018) Jan A. Burger et al. BLOOD
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL
- (2017) T Munir et al. LEUKEMIA
- Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL
- (2017) D R Howard et al. LEUKEMIA
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial
- (2011) Stefano Molica Expert Review of Anticancer Therapy
- Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression Analysis
- (2010) Dirk Bassler JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Stopping clinical trials early for benefit: impact on estimation
- (2009) Boris Freidlin et al. Clinical Trials
- Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
- (2009) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now